Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

July 17, 2020

Study Completion Date

March 27, 2021

Conditions
StrokeStroke, AcuteBrain Injury, Acute
Interventions
BIOLOGICAL

Umbilical Cord Blood

Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.

OTHER

Placebo

The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.

Trial Locations (6)

27157

Wake Forest Baptist Medical Center, Winston-Salem

27710

Duke University Medical Center, Durham

30303

Emory University School of Medicine, Atlanta

32610

University of Florida Health Shands Hospital, Gainesville

77030

Houston Methodist, Houston

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
collaborator

The Marcus Foundation

OTHER

collaborator

Emory University

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

lead

Joanne Kurtzberg, MD

OTHER

NCT03004976 - Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke | Biotech Hunter | Biotech Hunter